Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prognostic value of TP53 transcriptional activity on p21 and bax in patients with esophageal squamous cell carcinomas treated by definitive chemoradiotherapy.

International journal of radiation oncology, biology, physics - 1 Oct 2002

Michel Pierre, Magois Karine, Robert Valerie, Chiron Anne, Lepessot Florence, Bodenant Corinne, Roque Isabelle, Seng Sok K, Frebourg Thierry, Paillot Bernard

Abstract excerpt

PURPOSE: The aim of this study was to evaluate biologic factors on survival and clinical response after definitive concomitant chemoradiotherapy (CRT) in patients with esophageal squamous cell carcinoma (ESCC). METHODS AND MATERIALS: TP53 protein hyperexpression (immunochemistry [IHC]) and functional assay (FA) of TP53, measuring the ability of TP53 to transactivate p21 and bax reporter systems, were performed in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to bcl-2-Associated X Protein
Share to Cisplatin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Confidence Intervals

Share to Esophageal Neoplasms

Share to Fluorouracil

Share to Ploidies

Share to Proto-Oncogene Proteins c-bcl-2

Share to Transcriptional Activation

Source

Identifiers

PMID: 12243811
DOI: 10.1016/s0360-3016(02)02911-5

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prognostic value of TP53 transcriptional activity on p21 and bax in patients with esophageal squamous cell carcinomas treated by definitive chemoradiotherapy.PMID 12243811Read ↗

p53 Mutation status predicts pathological response to chemoradiotherapy in locally advanced esophageal cancer.Semantic proximity Read ↗

Expression and alteration of p53 and p21(waf1/cip1) influence the sensitivity of chemoradiation therapy for esophageal cancer.Semantic proximity Read ↗

Prognostic value of p53 mutations in patients with locally advanced esophageal carcinoma treated with definitive chemoradiotherapy.Semantic proximity Read ↗

Epidermal growth factor receptor, p53 mutation, and pathological response predict survival in patients with locally advanced esophageal cancer treated with preoperative chemoradiotherapy.Semantic proximity Read ↗

The p53 gene mutation is of prognostic value in esophageal squamous cell carcinoma patients in unified stages of curability.Semantic proximity Read ↗

Association of p53 protein expression with responses and survival of patients with locally advanced esophageal carcinoma treated with chemoradiotherapy.Semantic proximity Read ↗

The biomarker TP53 divides patients with neoadjuvantly treated esophageal cancer into 2 subgroups with markedly different outcomes. A p53 Research Group study.Semantic proximity Read ↗

Deregulated p21(WAF1) overexpression impacts survival of surgically resected esophageal squamous cell carcinoma patients.Semantic proximity Read ↗

p53 sequence analysis predicts treatment response and outcome of patients with esophageal carcinoma.Semantic proximity Read ↗

p53 functional activation is independent of its genotype in five esophageal squamous cell carcinoma cell lines.Semantic proximity Read ↗

TP53 mutations and pathologic complete response to neoadjuvant cisplatin and fluorouracil chemotherapy in resected oral cavity squamous cell carcinoma.Semantic proximity Read ↗

The TP53 genotype but not immunohistochemical result is predictive of response to cisplatin-based neoadjuvant therapy in stage III non-small cell lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.